Skip to main content

Table 1 Baseline characteristics of patients with PBT and those without PBT in different HCC stage subset in the entire cohort (n = 1255)

From: Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma

Variable

BCLC 0-A (n = 804)

BCLC B-C (n = 451)

PBT

n = 171)

Non-PBT

(n = 633)

P-value

PBT

(n = 176)

Non-PBT

(n = 275)

P-value

Demographic factors

 Age, yr

52.9 ± 12.5

50.9 ± 12.1

0.062

49.9 ± 12.2

49.1 ± 12.5

0.544

Sex, n (%)

 Male

139 (81.3)

557 (88.0)

0.220

157 (89.2)

249 (90.5)

0.644

 Female

32 (18.7)

76 (12.0)

 

19 (10.8)

26 (9.5)

 

HBsAg, n (%)

 Positive

143 (83.6)

545 (86.1)

0.415

148 (84.1)

228 (82.9)

0.743

 Negative

28 (16.4)

88 (13.9)

 

28 (15.9)

47 (17.1)

 

Cirrhosis, n (%)

 Yes

123 (71.9)

427 (67.5)

0.265

133 (75.6)

198 (72)

0.404

 No

48 (28.1)

206 (32.5)

 

43 (24.4)

77 (28)

 

Hemoglobin, g/L

129.7 ± 22.8

141.6 ± 17.5

< 0.001

131.2 ± 23.1

140.3 ± 19.9

0.000

Platelet count, × 109 /L

185.0 ± 64.5

201.3 ± 92.9

0.008

215.4 ± 113.3

207.1 ± 71.3

0.338

Prothrombin time, s

13.0 ± 1.6

12.7 ± 0.9

0.001

13.1 ± 1.1

12.7 ± 1.3

0.001

ALT, U/L, median (range)

39 (6565)

33 (71428)

0.024

42.5(8237)

38.0(6522)

0.189

ALBI grade, n (%)

 Grade 1

84 (49.1)

399 (63.0)

< 0.001

76 (43.2)

160 (58.2)

0.001

 Grade 2

84 (49.1)

232 (36.7)

 

99 (56.3)

115 (41.8)

 

 Grade 3

3 (1.8)

2 (0.3)

 

1 (0.5)

0

 

Inflammatory factors

 NLR, median (range)

2.4 (0.5,13.0)

1.9 (0.3,24.9)

< 0.001

2.5 (0.9,24.4)

2.3 (0.6,18.3)

0.013

 PLR, median (range)

121.1 (21.61432.1)

96.9 (19.4414.0)

< 0.001

133.9 (19.8751.0)

119.6 (20.6314.6)

< 0.001

 APRI, median (range)

0.6 (0.1,12.2)

0.5 (0.1,21.1)

0.038

0.6 (0.1,3.8)

0.5 (0.1,5.7)

0.079

Tumor characteristics

 AFP, ug/L

   ≥ 400

99 (42.1)

214 (33.8)

0.044

88 (50)

149 (54.2)

0.387

   < 400

72 (57.9)

419 (66.2)

 

88 (50)

126 (45.8)

 

  Tumor size, cm

9.2 ± 6.1

6.2 ± 3.1

< 0.001

10.7 ± 3.92

8.9 ± 3.5

< 0.001

Tumor number, n (%)

 Solitary

167 (97.7)

596 (94.2)

0.049

59 (33.5)

87 (31.6)

0.975

 2

4 (2.3)

29 (4.6)

 

59 (33.5)

102 (37.1)

 

 3

0 (0)

8 (1.2)

 

18 (10.2)

25 (9.1)

 

 4

0 (0)

0 (0)

 

40 (22.8)

61 (22.2)

 

Tumor capsule, n (%)

 Complete

137 (80.1)

574 (90.7)

< 0.001

107 (60.8)

187 (68)

0.118

 Incomplete

34 (19.9)

59 (9.3)

 

69 (39.2)

88 (32)

 

Differentiation, n (%)

 I+ II

115 (67.3)

465 (73.5)

0.108

119 (67.6)

193 (70.2)

0.566

 III, IV

56 (32.7)

168 (26.5)

 

57 (32.4)

82 (29.8)

 

MVI, n (%)

 Yes

50 (29.2)

123 (19.4)

0.006

79 (44.9)

105 (38.2)

0.158

 No

121 (70.8)

510 (80.6)

 

97 (55.1)

170 (61.8)

 

PVTT, n (%)

 Yes

0

0

 

100 (56.8)

116 (42.2)

0.002

 No

171 (100)

633 (100)

 

76 (43.2)

159 (57.8)

 

HVTT, n (%)

     

0.000

 Yes

0

0

 

21 (11.9)

7 (2.5)

 

 No

171 (100)

633 (100)

 

155 (88.1)

268 (97.5)

 

Surgical factors

 Extent of resection, n (%)

  Major

64 (37.4)

194 (30.6)

0.092

126 (71.6)

180 (65.5)

0.174

  Minor

107 (62.6)

439 (69.4)

 

50 (28.4)

95 (34.5)

 

Type of resection, n (%)

 Anatomical

62 (36.3)

203 (32.1)

0.302

97 (55.1)

150 (54.5)

0.906

  Nonanatomical

109 (63.7)

430 (67.9)

 

79 (44.9)

125 (45.5)

 

Resection margin

  ≤ 1 cm

32 (18.7)

58 (9.2)

< 0.001

56 (31.8)

122 (44.4)

0.008

  > 1 cm

139 (81.3)

575 (90.8)

 

120 (68.2)

153 (55.6)

 

Pringle maneuver, n (%)

 Yes

111 (64.9)

380 (60.0)

0.245

114 (64.8)

169 (61.4)

0.477

 No

60 (35.1)

253 (40.0)

 

62 (35.2)

106 (38.6)

 

 Blood loss, ml, median (range)

1484.7 (200,12,000)

200 (50,3000)

< 0.001

1000 (200,10,500)

300 (30,2500)

< 0.001

Clavien-Dindo grade

 I

4 (2.3)

9 (1.4)

0.045

3 (1.7)

8 (2.9)

0.950

 II

1 (0.6)

9 (1.4)

 

2 (1.1)

4 (1.5)

 

 III

15 (8.8)

31 (4.9)

 

10 (5.7)

18 (6.5)

 

 IV

2 (1.2)

3 (0.5)

 

3 (1.7)

2 (0.7)

 
  1. Abbreviation: HBsAg Hepatitis B surface antigen, ABLI grade albumin to bilirubin grade, ALT anlanine transaminase, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, APRI alanine transaminase to platelet ratio index, PVTT portal vein tumor thrombus, HVTT hepatic vein tumor thrombus, MVI microscopic vascular invasion, AFP alpha fetoprotein